We are live on
!
Find out more
iBio
IBIO
IBIO
43 hedge funds and large institutions have $4.97M invested in iBio in 2022 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 11 reducing their positions, and 14 closing their positions.
New
Increased
Maintained
Reduced
Closed
16% more call options, than puts
Call options by funds: $85K | Put options by funds: $73K
0% more ownership
Funds ownership: 0.03% → 0.03% (+0%)
19% less funds holding
Funds holding: 53 → 43 (-10)
35% less capital invested
Capital invested by funds: $7.63M → $4.97M (-$2.66M)
36% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 11
64% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 14
Holders
43
Holders Change
-10
Holders Change %
-18.87%
% of All Funds
0.74%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
7
Reduced
11
Closed
14
Calls
$85K
Puts
$73K
Net Calls
+$12K
Net Calls Change
-$21K
Top Buyers
| 1 |
BlackRock
New York
|
+$782K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$228K |
| 3 |
N
Natixis
Paris,
France
|
+$53.1K |
| 4 |
Charles Schwab
San Francisco,
California
|
+$49.8K |
| 5 |
Renaissance Technologies
New York
|
+$37.6K |
Top Sellers
| 1 |
Millennium Management
New York
|
-$602K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$141K |
| 3 |
Goldman Sachs
New York
|
-$78K |
| 4 |
Morgan Stanley
New York
|
-$74.9K |
| 5 |
E
Ergoteles
New York
|
-$53.3K |
